Toxin-like peptides in plasma, urine and faecal samples from COVID-19 patients
Open Access
- 14 October 2021
- journal article
- research article
- Published by F1000 Research Ltd in F1000Research
- Vol. 10, 550
Abstract
Background: SARS-CoV-2 that causes COVID-19 disease and led to the pandemic currently affecting the world has been broadly investigated. Different studies have been performed to understand the infection mechanism, and the involved human genes, transcripts and proteins. In parallel, numerous clinical extra-pulmonary manifestations co-occurring with COVID-19 disease have been reported and evidence of their severity and persistence is increasing. Whether these manifestations are linked to other disorders co-occurring with SARS-CoV-2 infection, is under discussion. In this work, we report the identification of toxin-like peptides in COVID-19 patients by application of the Liquid Chromatography Surface-Activated Chemical Ionization – Cloud Ion Mobility Mass Spectrometry. Methods: Plasma, urine and faecal samples from COVID-19 patients and control individuals were analysed to study peptidomic toxins’ profiles. Protein precipitation preparation procedure was used for plasma, to remove high molecular weight proteins and efficiently solubilize the peptide fraction; in the case of faeces and urine, direct peptide solubilization was employed. Results: Toxin-like peptides, almost identical to toxic components of venoms from animals, like conotoxins, phospholipases, phosphodiesterases, zinc metal proteinases, and bradykinins, were identified in samples from COVID-19 patients, but not in control samples. Conclusions: The presence of toxin-like peptides could potentially be connected to SARS-CoV-2 infection. Their presence suggests a possible association between COVID-19 disease and the release in the body of (oligo-)peptides almost identical to toxic components of venoms from animals. Their involvement in a large set of heterogeneous extra-pulmonary COVID-19 clinical manifestations, like neurological ones, cannot be excluded. Although the presence of each individual symptom is not selective of the disease, their combination might be related to COVID-19 by the coexistence of the panel of the here detected toxin-like peptides. The presence of these peptides opens new scenarios on the aetiology of the COVID-19 clinical symptoms observed up to now, including neurological manifestations.Keywords
Funding Information
- European Commission Joint Research Centre
This publication has 45 references indexed in Scilit:
- Conotoxins Targeting Nicotinic Acetylcholine Receptors: An OverviewMarine Drugs, 2014
- Secreted Phospholipases A2 of Snake Venoms: Effects on the Peripheral Neuromuscular System with Comments on the Role of Phospholipases A2 in Disorders of the CNS and Their Uses in IndustryToxins, 2013
- Surface‐activated chemical ionization and cation exchange chromatography for the analysis of enterotoxin AJournal of Mass Spectrometry, 2009
- NCBI BLAST: a better web interfaceNucleic Acids Research, 2008
- Development and applications of surface‐activated chemical ionizationMass Spectrometry Reviews, 2007
- Molecular mechanisms of neurotoxin action on voltage-gated sodium channelsBiochimie, 2000
- Basic local alignment search toolJournal of Molecular Biology, 1990
- Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo‐oxygenase/PGE isomeraseBritish Journal of Pharmacology, 1989
- The use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genesCell, 1984
- The Polymerization of Acetonitrile in the Presence of Acidic and Basic SubstancesBulletin of the Chemical Society of Japan, 1966